-
公开(公告)号:WO2012149280A3
公开(公告)日:2014-05-08
申请号:PCT/US2012035401
申请日:2012-04-27
Applicant: ABBOTT LAB , FRANK KRISTINE E , BURCHAT ANDREW , COX PHILIP , IHLE DAVID C , MULLEN KELLY D , SOMAL GAGANDEEP , VASUDEVAN ANIL , WANG LU , WILSON NOEL S
Inventor: FRANK KRISTINE E , BURCHAT ANDREW , COX PHILIP , IHLE DAVID C , MULLEN KELLY D , SOMAL GAGANDEEP , VASUDEVAN ANIL , WANG LU , WILSON NOEL S
IPC: A01N43/54 , C07D401/04 , C07D471/04
CPC classification number: C07D487/14
Abstract: The invention provides compounds of Formula (I), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式(I)的化合物,其药学上可接受的盐,前药,生物活性代谢物,立体异构体和异构体,其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
公开(公告)号:WO2007117465A3
公开(公告)日:2008-08-28
申请号:PCT/US2007008307
申请日:2007-04-02
Applicant: ABBOTT LAB , ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
Inventor: ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式(I)的新型化合物或其药学上可接受的盐,前体药物和式(I)的生物活性代谢物,其中取代基如本文所定义,其可用作治疗剂。
-
公开(公告)号:EP2001480A4
公开(公告)日:2011-06-15
申请号:EP07754773
申请日:2007-04-02
Applicant: ABBOTT LAB
Inventor: ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/196 , A61P35/00 , C07D403/12
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
-
公开(公告)号:UY33659A
公开(公告)日:2012-04-30
申请号:UY33659
申请日:2011-10-07
Applicant: ABBOTT LAB
Inventor: ANIL VASUDEVAN , BIN LI , MULLEN KELLY D , CALDERWOOD DAVID J , WILSON NOEL S , PHILIP COX , HOEMANN MICHAEL Z , CLAPHAM BRUCE , VILLAMIL CLARA I , GAGANDEEP SOMAL
IPC: A61K31/505 , A61K31/519 , A61P29/00 , A61P35/00 , C07D491/00 , C07D491/04 , C07D491/044 , C07D491/048
Abstract: Compuestos novedosos de fórmula (I), sales, metabolitos con actividad biológica, prodrogas, racematos, enantiómeros, diastereómeros, solvatos e hidratos farmacéuticamente aceptables de éstos, donde las variables son como se las define en la presente . Los compuestos de fórmula (I) son útiles como inhibidores de quinasas, por lo que han de resultar de utilidad para tratar determinadas afecciones y enfermedades, especialmente afecciones y enfermedades inflamatorias y afecciones y trastornos proli ferativos, por ejemplo, cánceres.
-
公开(公告)号:CA2781010A1
公开(公告)日:2011-06-09
申请号:CA2781010
申请日:2010-12-01
Applicant: ABBOTT LAB
Inventor: WISHART NEIL , ARGIRIADI MARIA A , BREINLINGER ERIC C , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQUIN C , MORYTKO MICHAEL J , MULLEN KELLY D , SOMAL GAGANDEEP , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R , HOEMANN MICHAEL Z
IPC: C07D471/14 , C07D487/14 , C07D498/14 , C07D513/14 , C07D519/00
Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
公开(公告)号:GT201300214A
公开(公告)日:2014-10-17
申请号:GT201300214
申请日:2013-09-13
Applicant: ABBOTT LAB
Inventor: CUSACK KEVIN P , GORDON THOMAS D , IHLE DAVID C , HAYES MARTIN E , BREINLINGER ERIC C , ERICSSON ANNA M , LI BIN , WANG LEI , MARTÍNEZ 9 GLORIA Y , BURCHAT ANDREW , HOBSON ADRIAN D , MULLEN KELLY D , FRIEDMAN MICHAEL , MORYTKO MICHAEL J
IPC: A01N27/00 , A61K31/015
Abstract: LA INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA (I), SALES FARMACÉUTICAMENTE ACEPTABLES, PROFÁRMACOS, METABOLITOS BIOLÓGICAMENTE ACTIVOS, ESTEREOISÓMEROS E ISÓMEROS DE LOS MISMOS, EN EL QUE LA VARIABLE SE DEFINEN EN EL PRESENTE DOCUMENTO.LOS COMPUESTOS DE LA INVENCIÓN SON ÚTILES PARA EL TRATAMIENTO DE CONDICIONES INMUNOLÓGICOS Y ONCOLÓGICOS.
-
公开(公告)号:ECSP12011968A
公开(公告)日:2012-07-31
申请号:ECSP12011968
申请日:2012-06-12
Applicant: ABBOTT LAB
Inventor: WOLLER KEVIN ROGER , WISHART NEIL , FRIEDMAN MICHAEL , STEWART KENT D , WALLACE GRIER A , BREINLINGER ERIC C , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , GEORGE DAWN M , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , VOSS JEFFREY W , WANG LU , CALDERWOOD DAVID J , GOEDKEN ERIC R , ARGIRIADI MARÍA A , MULLEN KELLY D , SOMAL GAGANDEEP , HOEMANN MICHAEL Z
Abstract: La invención proporciona un compuesto de fórmula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), Ii), (Ij), (Ik), o (Il), como se define en la presente, las sales farmacéuticamente aceptables, profármacos, metabolitos biológicamente activos, estereoisómeros e isómeros del mismo, en los que las variables se definen en la presente. Los compuestos de la invención son útiles para tratar enfermedades inmunológicas y oncológicas.
-
公开(公告)号:SG181147A1
公开(公告)日:2012-07-30
申请号:SG2012039905
申请日:2010-12-01
Applicant: ABBOTT LAB
Inventor: HOEMANN MICHAEL Z , WISHART NEIL , ARGIRIADI MARIA A , BREINLINGER ERIC C , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , MULLEN KELLY D , SOMAL GAGANDEEP , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R
Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
公开(公告)号:CA2644910A1
公开(公告)日:2007-10-18
申请号:CA2644910
申请日:2007-04-02
Applicant: ABBOTT LAB
Inventor: ABBOTT LILY K , CUSACK KEVIN P , ARGIRIADI MARIA A , CALDERWOOD DAVID J , ZHANG XIAOLEI , MULLEN KELLY D , DIXON RICHARD W , GORDON THOMAS D , TALANIAN ROBERT V , WANG LU X , LI BIQIN , WU XIAOYUN , FRANK KRISTINE E , BORHANI DAVID W , ERICSSON ANNA M , BURCHAT ANDREW , WISHART NEIL , BARBERIS CLAUDE E
IPC: A61K31/5377
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
-
公开(公告)号:CA2644910C
公开(公告)日:2014-01-28
申请号:CA2644910
申请日:2007-04-02
Applicant: ABBOTT LAB
Inventor: ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/5377
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
-
-
-
-
-
-
-
-
-